WASHINGTON, DC – The Center for Strategic and International Studies (CSIS), a bipartisan, nonprofit policy research organization dedicated to advancing practical ideas to address the world’s greatest ...

HYDERABAD, (IANS) – In a setback for Jhansi Reddy, a member of the Congress party, her application for Indian citizenship has been denied by Indian authorities. Jhansi Reddy, who holds American ...

Add Yahoo as a preferred source to see more of our stories on Google. Jan 28 (Reuters) - India's Gland Pharma reported a nearly 28% jump in third-quarter profit on Wednesday, boosted by strong sales ...

Beginning in 2026, the ACC's Distinguished Award for International Service will be named in honor of Navin C. Nanda, MD, FACC, thanks to the support of the American Association of Cardiologists of ...

Last month, the United States and Saudi Arabia signed the Strategic Artificial Intelligence Partnership. On the heels of a May 2025 agreement with the United Arab Emirates (UAE), the United States has ...

Here’s a trio for you: Taylor Swift’s record-shattering The Life Of A Showgirl; Bad Bunny’s culture-defining residency in Puerto Rico (and subsequent, idiot-bothering confirmation for the Super Bowl ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min AAR's $78M acquisition of HAECO ...

Dr. Reddy’s Laboratories remains a compelling buy due to underappreciated growth in biosimilars and GLP-1 segments, despite near-term headwinds. RDY's Q2 FY26 results showed modest revenue growth, ...

Monday - Friday, 11:00 - 12:00 SIN/HK | 0500 - 06:00 CET In this video Dr Reddy's CEO Erez Israeli says the pivot is already visible - India and Europe growth is now driven by innovation, consumer ...

Anil Sharma’s Lila Global has recruited dry bulk veteran Navin Arjun Soni as chief commercial officer. Soni, who until recently headed Heidmar’s Singapore office, where he spent nearly three years ...

Dr. Reddy 's Laboratories is betting big on a new wave of growth fueled by a global demand for weight-loss drugs — by launching its own lower-cost version of semaglutide, the blockbuster ingredient ...